The Claim

In adults with metabolic dysfunction-associated steatotic liver disease (MASLD), the Framingham Risk Score and Pooled Cohort Equation exhibit poor discrimination for cardiovascular events, with C-statistics of 0.58 and 0.60 respectively, and systematically overpredict risk in high-risk deciles and underpredict risk in low-risk deciles, indicating inadequate risk stratification performance.

Source: Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
52score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Description
1 study reviewed
In plain English

In people with metabolic dysfunction-associated steatotic liver disease, two commonly used heart disease risk calculators—Framingham Risk Score and Pooled Cohort Equation—do not accurately identify who will have a cardiovascular event. They overestimate risk in high-risk groups and underestimate risk in low-risk groups.

See the scientific wording

In adults with metabolic dysfunction-associated steatotic liver disease (MASLD), the Framingham Risk Score and Pooled Cohort Equation poorly discriminate individuals who will experience cardiovascular events, with C-statistics of 0.58 and 0.60 respectively, and significantly misestimate risk across the population, overpredicting in high-risk deciles and underpredicting in low-risk deciles, indicating current tools are inadequate for this population.

Why this might work

Fat buildup in the liver changes how the body processes fats and triggers chronic inflammation, which affects blood vessels and heart function in ways that standard risk calculators don't account for, leading to wrong predictions about who will have a heart event.

Suggested mechanismbased on 1 study

What the research says

1 study
  1. Study: Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.

    For people with MASLD, standard heart risk calculators are like broken thermometers—they often say someone is at high risk when they’re not, and low risk when they actually are. This study proves these tools don’t work well for this group.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.